Held by 2 specialist biotech funds
**Signal Note: Eventide Infrastructure Allocation Shift** Eventide's $709K STRL position represents a notable portfolio reallocation away from pure-play biotech into infrastructure—an unusual move for this values-focused manager with historically concentrated life sciences exposure. The timing suggests either portfolio rebalancing or conviction in infrastructure-linked secular tailwinds, though the position size remains modest relative to typical Eventide biotech holdings and warrants monitoring for strategic intent signals in future filings.